Drugs in development · updated 30 October 2026
Stroke: drugs in development
As of 30 October 2026 there are 81 active clinical trials (recruiting or ongoing, phases I–III) on 70 drugs for stroke. 23 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| CenvacibartREGN7508 | III | 3 | NCT07626411 |
| [18F]-FEOBV | III | 1 | NCT03998852 |
| Dimephosphon | III | 1 | NCT07167550 |
| MLC1501 | II–III | 1 | NCT05046106 |
| NoNO-42 | III | 1 | NCT06352632 |
| Pelacarsen | III | 1 | NCT07517263 |
| Polycap | III | 1 | NCT05963568 |
| Recaticimab | III | 1 | NCT07002476 |
| Sovateltide | III | 1 | NCT05691244 |
| Anisodine Hydrobromide | II | 2 | NCT07800572 |
| Abelacimab | II | 1 | NCT04755283 |
| BB-031 | II | 1 | NCT06226805 |
| CC-101 | II | 1 | NCT07709845 |
| J147 Emulsion for Injection | II | 1 | NCT07430917 |
| NTS-521 | II | 1 | NCT07742098 |
| REGN9933 | II | 1 | NCT07175428 |
| Relaxin | I–II | 1 | NCT07359872 |
| TBO-309 | II | 1 | NCT05363397 |
| VERVE-102 | II | 1 | NCT07839936 |
| N-DimethyltryptamineDimethyltryptamine | I | 1 | NCT05559931 |
| Nicotinamide ribosideNicotinamide ribonucleoside | I | 1 | NCT06280482 |
| PsilocybinPsilocybine | I | 1 | NCT07053917 |
| SNE-101 | I | 1 | NCT06995625 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| TenecteplaseTnkase®, Metalyse® | II–III | 12 | NCT05105633 |
| AspirinVazalore®, Durlaza® | III | 7 | NCT05047172 |
| ApixabanEliquis, Abanta® | III | 6 | NCT07626411 |
| ColchicineColchicin, Lodoco® | III | 6 | NCT04774159 |
| CilostazolPletal® | III | 4 | NCT07174414 |
| ClopidogrelClopidgrel, Clopidogrel Zentiva (previously Clopidogrel Winthrop)® | III | 3 | NCT05047172 |
| RivaroxabanRivoroxaban, Yulzety® | III | 3 | NCT05047172 |
| RosuvastatinEzallor Sprinkle®, Crestor® | III | 3 | NCT06358313 |
| AlteplaseActivase®, Cathflo Activase® | III | 2 | NCT07687056 |
| AtorvastatinLipitor, Atorvaliq® | III | 2 | NCT06358313 |
| Botulinum toxin type ANuceiva® | II–III | 2 | NCT06296082 |
| DeferoxamineDesferal® | III | 2 | NCT06763055 |
| EdoxabanSavaysa®, Roteas® | III | 2 | NCT07454707 |
| TicagrelorBrilinta®, Brilique® | III | 2 | NCT05047172 |
| TocilizumabTociluzumab, Avtozma | III | 2 | NCT07263776 |
Sorted by most advanced phase and number of active trials. Showing 15 of 47 drugs.
All 70 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Ischemic stroke 94 drugs
- Ischemic Attack, Transient 5 drugs
- Cerebral infarction 7 drugs
- Intracranial arteriosclerosis 8 drugs
- Cerebral small vessel diseases 5 drugs
- Atrial fibrillation 32 drugs
- Cerebral hemorrhage 23 drugs
- Brain stem infarction 3 drugs
- Brain infarction 3 drugs
- Lacunar stroke 4 drugs
- Patent foramen ovale 6 drugs
- Hypercholesterolemia 21 drugs
Broader categories
- Central nervous system disease 38 drugs
- Nervous System Diseases 39 drugs
- Vascular disease 16 drugs
- Brain Diseases 23 drugs
- Cerebrovascular disease 8 drugs
- Cardiovascular disease 71 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D020521 “Stroke”.